#London #United Kingdom #VitaSmart #Bridge to Life #organ preservation

UK NICE's Recent Guidelines on Organ Preservation

In a significant advancement for organ transplantation, the UK’s National Institute for Health and Care Excellence (NICE) has recently endorsed routine funding through the National Health Service (NHS) for the VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) system, developed by Bridge to Life™ Ltd. This groundbreaking decision underscores the need for innovative technology to enhance the preservation of deceased donor livers prior to transplantation.

The VitaSmart™ system employs hypothermic oxygenated perfusion to maintain donor organs in optimal condition, significantly lessening risks associated with traditional static cold storage methods. Following a thorough evaluation, NICE concluded that advanced perfusion systems offer substantial clinical advantages over conventional techniques, including improved graft survival rates and reduced biliary complications, which are vital metrics in successful liver transplants.

Benefits of the VitaSmart™ System

The evidence supporting the efficacy of the VitaSmart™ system is compelling. Not only has it been proven to enhance clinical outcomes, but it also presents a more economically viable option in the long run. Don Webber, the CEO and President of Bridge to Life, hailed NICE's recommendation as a landmark achievement, highlighting its potential to establish hypothermic oxygenated perfusion as the new standard for care in liver transplantation.

NICE's endorsement is particularly timely as U.S. medical professionals are becoming acquainted with this technology following its FDA De Novo clearance, reinforcing the system’s reliability and clinical benefits across international borders. The simplicity of the VitaSmart™ system ensures that it can smoothly integrate into existing clinical workflows without the high costs and complexities often associated with normothermic systems.

Expanding Access to Advanced Technology

Rebbeca Sanabria Mateos, a Consultant Liver Transplant Surgeon at the University Hospitals Birmingham NHS Foundation Trust, emphasized the importance of equitable access to advanced perfusion technology. She stated that the introduction of the VitaSmart™ system would allow surgical teams to utilize extended-criteria donor organs more confidently, thereby improving patient outcomes while streamlining operating room processes.

Bridge to Life is at the forefront of expanding evidence-based preservation science, and this development marks a defining moment in the company's trajectory. With widespread acceptance of the VitaSmart™ system in Europe, as well as commercial growth in the United States, the company is poised to redefine the landscape of organ preservation. It is consistently investing in scientific innovation that not only broadens the donor pool but also improves care for recipients.

A Leap towards Better Outcomes

NICE’s guidance signifies a new era for liver transplantation programs in the UK, paving the way for improved patient care through innovative organ preservation techniques. The combination of meaningful clinical benefits and the goal of expanding donor organ availability could transform the realities of organ transplantation in the near future.

About Bridge to Life™ Ltd.

Founded with a mission to advance organ preservation and perfusion technology, Bridge to Life™ Ltd. continues to deliver cutting-edge solutions to medical teams globally. The VitaSmart™ system is a vital addition to their established products, including the Belzer UW®, which is recognized as the gold standard in cold static preservation. Together, these technologies reflect Bridge to Life's commitment to improving patient outcomes and revolutionizing organ transplantation practices.

With NICE's endorsement now in place, the future looks bright for innovative preservation technologies in the UK healthcare system, and increasingly, the global market will likely follow suit as they recognize the importance of effective and efficient organ preservation systems.